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Abstract
Objective: To assess possible factors associated with the loss of antibodies to hepatitis 
A 7 years after the primary immunization in children of HIV-infected mothers and the 
response to revaccination in patients seronegative for hepatitis A.
Methods: Quantification of HAV antibodies by electrochemiluminescence was performed 
in 39 adolescents followed up at the Pediatric Aids Clinic of Federal University of São 
Paulo (Unifesp): 29 HIV-infected (HIV group) (median age: 12.8 years) and 10 HIV-exposed 
but non-infected (ENI group) (median age: 13.4 years). All of them received two doses of 
HAV vaccine (Havrix®) in 2002.
Results: The median age at primary immunization (PI) was 5.4 years for HIV group and 
6.5 years for ENI group. All children, from both groups, had antibodies to HAV >20 mIU/mL 
after PI. Seven years later, the ENI group showed a median concentration of antibodies = 
253.5 mIU/mL, while the HIV group = 113.0 mIU/mL (Mann-Whitney test, p=0.085). All ENI 
group and 23/29 (79.3%) from HIV group mantained HAV antibodies 7 years after PI. The 
levels of hepatitis A antibodies in the primary vaccination were the only factor indepen-
dently associated with maintaining these antibodies for 7 years. The group that lost HAV 
seropositivity was revaccinated and 83.3% (5/6) responded with antibodies >20 mUI/mL.
Conclusions: The antibodies levels acquired in the primary vaccination in the HIV group 
were the main factor associated with antibodies loss after HAV immunization.
© 2015 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. All rights 
reserved.
DOI of original article: http://dx.doi.org/10.1016/j.rpped.2014.09.005
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Persistência de anticorpos contra o vírus da hepatite A após imunização primária 
e resposta à revacinação em crianças e adolescentes com exposição perinatal ao HIV
Resumo
Objetivo: Avaliar possíveis fatores associados à perda de anticorpos para o vírus da hepa-
tite A (VHA) sete anos após a imunização primária e resposta à revacinação em crianças 
nascidas de mães soropositivas para HIV nos pacientes soronegativos para Hepatite A.
Métodos: Quantificação de anticorpos para o VHA por meio da eletroquimioluminescên-
cia foi feita em 39 adolescentes acompanhados no Ambulatório de Aids Pediátrica da 
Universidade Federal de São Paulo (Unifesp): 29 infectados pelo HIV e 10 expostos e não 
infectados (ENI) pelo HIV, com mediana de idade, respectivamente, de 12,8 e 13,4 anos. 
Todos receberam duas doses da vacina VHA (Havrix®) em 2002.
Resultados: A mediana da idade na época da imunização primária (IP) era de 5,4 anos 
para o grupo HIV e 6,5 anos para o grupo ENI. As crianças dos dois grupos apresentaram 
anticorpos para o VHA > 20 mUI/mL após a IP. Sete anos após, o grupo ENI apresentava 
mediana de anticorpos = 253,5 mUI/mL e o grupo HIV = 113,0 mUI/mL (Mann-Whitney; 
p=0,085). Todo grupo ENI e 23/29 (79,3%) do grupo HIV mantiveram anticorpos contra o 
VHA sete anos após IP. Os níveis de anticorpos para hepatite A na primo vacinação foram 
o único fator independentemente associado à manutenção desses anticorpos decorridos 
sete anos. O grupo que perdeu soropositividade para VHA foi revacinado e 83,3% (5/6) 
responderam com anticorpos >20 mUI/mL.
Conclusões: Os níveis de anticorpos obtidos na primo vacinação no grupo HIV foram o 
principal fator associado à perda de anticorpos após imunização VHA.
© 2015 Sociedade de Pediatria de São Paulo. Publicado por Elsevier Editora Ltda. Todos os 
direitos reservados.
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Introduction
In recent years, advances in the diagnosis, treatment, and 
clinical and laboratory monitoring of the infection by the 
human immunodeficiency virus (HIV) in children have 
allowed longer survival and better quality of life for this 
population.1,2 In this sense, it is important to vaccinate HIV-
infected children who will reach adulthood and monitor the 
maintenance of antibodies after vaccination.
To monitor and revaccinate HIV-infected patients when 
necessary can prevent vaccine-preventable disease out-
breaks in this population.3 To protect adolescents infected 
with HIV against infection by the hepatitis A virus (HAV) is 
need, considering that the HIV/HAV coinfection can influ-
ence the clinical course of hepatitis A4 and be associated 
with an increase in HIV replication.5,6 Additionally, during 
adolescence, these individuals are more prone to liver dis-
orders when exposed to sexually-transmitted diseases 
(STDs), prolonged use of antiretroviral drugs and opportu-
nistic conditions.
A previous study carried out in the Service Center of the 
Division of Pediatric Infectious Diseases of Universidade 
Federal de São Paulo (CEADIPe/UNIFESP)7 showed that two 
doses of vaccine against hepatitis A, in addition to being 
well tolerated, resulted in an antibody titer >20 mUI/mL in 
children with perinatal HIV exposure, both infected ones 
and those exposed and non-infected (ENI).
The objective of this study was to analyze the per-
sistence of antibodies against HAV seven years after the 
primary immunization and possible associated factors, as 
well as the response to revaccination of children and ado-
lescents with perinatal exposure to HIV.
Method
This is a prospective cohort study with intervention, carried 
out between December 2009 and January 2011 in the 
Service Center of the Discipline of Pediatric Infectious 
Diseases (CEADIPe) of Universidade Federal de São Paulo 
(UNIFESP) and approved by the Institutional Review Board 
of Hospital São Paulo/Universidade Federal de São Paulo 
(UNIFESP). The free and informed consent form was signed 
by parents or guardians of all adolescents included in the 
study (CEP 1710/06).
A previous study on seroprevalence carried out at the 
Service identified children and adolescents who were 
seronegative for hepatitis A,8 who received two doses of 
the hepatitis A vaccine (Havrix; Glaxo SmithKline 
Beecham, Rixensart, Belgium) between 2002 and 2003, 
with a six months interval between doses.7 At the time of 
primary immunization,7 only those infected with HIV 
through vertical transmission were included; and the fol-
lowing were excluded from the study: patients who had 
serological evidence of previous infection with hepatitis 
viruses A, B or C, the ones who had received immuno-
globulin in the previous six months, those who were 
using immunosuppressive drugs, or HIV-infected children 
who belonged to the clinical category C and immunolog-
ical category 3.
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Of the 32 HIV-infected patients who received primary 
immunization,7 two were not currently undergoing regular 
monitoring at the service, and one received an additional 
dose of hepatitis A vaccine. Thus, a total of 29 patients 
infected with HIV (HIV Group) were included in this study. 
Of the 27 patients exposed to HIV who were non-infected 
and received primary immunization,7 only 10 (ENI Group) 
are being followed at the service and were included in the 
present study. Hence, 39 of these subjects who were regu-
larly followed at the service were included.
Clinical data of patients were obtained from the review 
of medical records: clinical and immunological category for 
HIV infection (CDC 1994)9; weight and height measurements 
used to calculate the Z-score for body mass index (BMI 
z-score) and z-scores for height/age (H/A z-scores) accord-
ing to the reference standards and recommendations by 
the World Health Organization10; clinical events; hospital-
izations, and age at start of antiretroviral therapy pre-
scribed to the HIV Group.
As part of the routine clinical follow-up, patients in the 
HIV group underwent assessment of CD4+ T lymphocyte 
count and viral load (VL) of HIV every four months. CD4+ T 
cells were assessed by flow cytometry (FACS Calibur, BD 
Biosciences, Franklin Lakes, USA). The HIV viral load quan-
tification was performed through RT-PCR (Cobas Amplicor) 
HIV-1 Monitor kit (Roche Diagnostics System, Basel, 
Switzerland) and Bayer Versant human immunodeficiency 
virus type 1 (HIV-1) RNA 3.0 (B-DNA) (Bayer, Tarrytown, New 
York). The following data were collected: CD4 + T lympho-
cyte count and HIV viral load quantification 30 days after 
primary vaccination and seven years later.
Quantification of total antibodies against HAV was per-
formed using electrochemiluminescence by means of a 
commercial Elecsys Anti-HAV kit (Roche Diagnostics, 
Indianapolis, USA) seven years after the primary immuniza-
tion. Plasma samples with antibody concentrations ≥20mIU/
mL were considered positive, and those <20 mIU/mL were 
considered negative. A new measurement of hepatitis A 
antibodies was performed by electrochemiluminescence in 
stored samples related to 30 days after the primary vacci-
nation (seven years before).
All patients with antibody concentration <20 mIU/mL for 
HAV received two doses of the same vaccine used in the 
primary vaccination seven years before (Havrix), adminis-
tered intramuscularly with an interval of six months 
between doses.
The statistical analysis for categorical variables was per-
formed using the chi-square test, and the Mann-Whitney 
test was used for the quantitative ones. Factors associated 
with maintenance of hepatitis A antibodies >20 IU/mL were 
analyzed using uni- and multivariate logistic regression. 
Thus, in search of possible factors that could differentiate 
patients from the HIV Group who lost their HAV seropositiv-
ity (anti-HAV antibodies <20 mIU/mL) during the period, 
from the ones who kept the seropositivity, some clinical, 
virological, and immunological events were assessed. The 
calculation of the odds ratio was performed using logarith-
mic transformation for the variables CD4+ T lymphocyte 
count, HIV viral load and quantification of HAV antibodies. 
Considering the sample size (n=29), the multivariate model 
could have a maximum of two explanatory variables, in 
addition to the adjustment constant of the model. Thus, to 
verify which variables were independently associated to 
the response, we adjusted the models containing a maxi-
mum of two of the following variables: CD4+ T lymphocyte 
count in the primary vaccination (CD4 PV), CD4+ T lympho-
cyte count seven years after the primary vaccination (CD4 
7 years after PV), viral load seven years after the primary 
vaccination (VL 7 years after PV), episode of herpes zoster, 
and hepatitis A antibodies after the primary vaccination 
(HAV AB after PV). The variables VL seven years after the 
PV and HAV AB after PV were included in the adjustment as 
numerical variables, since in the univariate analysis, VL 
seven years after PV produced no adjustment in the Odds 
Ratio when categorized, and HAV AB after PV showed wide 
confidence interval when categorized. The level of statisti-
cal significance was set at p<0.05. Statistical analysis was 
performed using the Statistical Package for Social Sciences 
16.0 (SPSS Inc. Chicago, IL, USA).
Results
Both groups were similar regarding age, H/A z-score, and 
BMI z-score (Table 1). All individuals in the ENI group, and 
23/29 of individuals from the HIV group were seropositive 
for hepatitis A (HAV antibodies ≥20 mIU/mL) (Table 1). The 
levels of HAV antibodies showed no statistically significant 
differences between the two groups seven years after the 
primary immunization (HIV Group: 113.0 mIU/mL and ENI 
Group: 253.5mIU/mL; Mann-Whitney test, p=0.08). Both 
groups (HIV and ENI) showed significant decrease in the 
levels of HAV antibodies seven years after the primary vac-
cination (Fig. 1).
The following events showed a statistically significant 
difference between the groups in the univariate analysis: 
number of patients with herpes zoster, antibody levels 30 
days after the primary vaccination, CD4 + T lymphocytes at 
Table 1 Characterization of the study population.
Characterization of Patients HIV Group (n=29) ENI Group (n=10) p
Age in years [median (min; max)] 12.8 (9.7; 16.8) 13.4 (10.9; 16.9) 0.64
Female gender (%) 48 30 0.31
E/I Z-score [median (min; max)] –0.47 (–2.21; +1.44) +0.12 (–1.60; +1.28) 0.08
BMI Z-score [median (min; max)] –0.10 (–2.64; +1.70) –0.29 (–1.31; +1.64) >0.99
Immune patients 7 years after PV (%) 79 100 0.17
PV, primary vaccination.
Persistence of hepatitis A virus antibodies after primary immunization 145
the primary vaccination and after seven years (Table 2). In 
the multivariate model, the only variable that was inde-
pendently associated with the maintenance of hepatitis A 
antibodies >20 mIU/mL was the level of hepatitis A antibod-
ies assessed 30 days after the primary vaccination, whether 
the assessment was quantitative or categorized (antibodies 
> or <1,000 mUI/mL).
The six patients who lost their seropositivity for HAV 
were revaccinated with two doses of vaccine against hepa-
titis A (Havrix), and five responded with antibody concen-
trations >20 mUI/mL. HAV-antibody levels are shown in 
Figure 2 at the following times: one month after the 1st 
booster dose, immediately before the 2nd booster dose, and 
one month after the 2nd booster dose.
Table 3 and Figures 3 and 4 show clinical, virological, and 
immunological features of patients who lost seropositivity 
for hepatitis A during this follow-up period of seven years.
Discussion
The HAV vaccine is known to be highly immunogenic in 
healthy individuals.11,12 Additionally, serum antibody levels 
remain for long periods after vaccination. Bian et al., in 
2010, in China, assessed 110 healthy children vaccinated 
against HAV and obtained a geometric mean of 61.6 mIU/
mL of antibodies, with antibody persistence in 99.1% of 
individuals 10 years after the immunization schedule.13
This study showed that 79% of adolescents and children 
infected with HIV through vertical transmission maintained 
the seropositivity against HAV seven years after the prima-
ry immunization schedule, with two vaccine doses. These 
results were similar, from a statistical point of view, when 
compared to the group of ten adolescents exposed to, but 
not infected by, HIV, where 100% maintained HAV seroposi-
tivity (Chi-square, p=0.174) (Table 1). Moreover, there was 
no statistical difference between the median antibody lev-
els of the two groups seven years after the primary vacci-
nation (Fig. 1). The impossibility of assessing all children 
immunized in the previous study7 may have been responsi-
ble for the lack of statistical significance between the two 
groups (type II error or b error).
However, it is worth mentioning that, for the final model 
(the one that showed only HAV AB after PV), the power 
obtained with α set at 5% was 98.6%, indicating that this 
model had high probability of detecting an actual differ-
ence between the groups.
Other groups have assessed the persistence of HAV anti-
bodies for shorter periods than the one analyzed in the 
present study and included patients with severe immuno-
suppression. Rigaud et al.,14 in 2008, observed 72% of sero-
conversion four weeks after vaccination, with a decrease to 
66% at week 52. Weinberg et al.,15 in 2009, showed a sero-
conversion of 97% at week 8 after vaccination, which 
decreased to 90% 18 months later. The group of HIV-infected 
patients studied here showed a decrease from 100% to 79% 
in the percentage of individuals with antibody levels 
≥20 mIU/mL for HAV in seven years. There is evidence of a 
decrease in vaccination antibody levels to other antigens in 
the population of HIV-infected children,3 even when they 
received antiretroviral therapy and were revaccinated.16 
The proportion of immune HIV-infected children decreased 
from 88% to 85% for measles, 84% to 61% for mumps, and 
100% to 79% in the case of rubella, three years after revac-
cination.16 Choudhury and Matin,17 in 2013, evaluated the 
persistence of tetanus toxoid antibodies in 24 HIV-infected 
children and observed levels >0.1 IU/mL in 62% of infected 
children and 100% of controls. These authors also showed 
that 71% responded to revaccination with levels >0.16 IU/
mL. They noted that HIV-infected children need a tetanus 
toxoid booster dose before the recommended revaccina-
tion time, which is 5-10 years.
Several factors seem to be involved in the response to 
vaccination and maintenance of antibody seropositivity in 
HIV-infected individuals. The immunological status18,19 and 
the HIV viral load20 at the time of vaccination are known to 
be important. Similarly, the clinical, immunological and 
virological course21 must influence the maintenance of vac-
cination antibody levels.
The presence of co-infection, such as hepatitis C, as well 
as male gender was associated with lower response to hep-
atitis A vaccine in adult HIV-infected patients.22 The main-
tenance of specific antibodies against vaccine antigens is 
associated with better maturation and preservation of B 
cell memory compartment when the combined antiretrovi-
ral therapy is started early in children.23 In the current 
study, children who lost hepatitis A antibodies started 
antiretroviral therapy at a later period, although this find-
ing was not statistically significant (p=0.19).
Disease progression caused by HIV occurs even in patients 
receiving antiretroviral therapy and undergoing stringent 
clinical follow-up. The six patients who lost their seroposi-
tivity for HAV were the ones with the most severe clinical 
and immunological impairment during the period, and only 
50% of them received antiretroviral therapy, although all of 
them had treatment indication. It is worth mentioning 
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Table 2 Univariate analysis of the HIV group according to maintenance of HAV antibodies 7 years after primary vaccination 
(HAV seropositive) and loss of HAV antibodies 7 years after primary vaccination (HAV seronegative).
HIV Group Odds Ratio 95%CI p-value
Seropositive Seronegative
VHA (n=23) VHA (n=6)
Age at PV 0.924
≤5.5 years 12 (52.2%) 3 (50.0%) 1.09 0.18-6.58
>5.5 years 11 (47.8%) 3 (50.0%) 1.00
Age at PV (years) 0.655
Median (Min-Max) 5.1 (1.9-9.3) 6.0 (3.2-9.0) 0.88 0.56-1.39
CD4 PV 0.049
≤1,000 5 (21.7%) 4 (66.7%) 1.00
>1,000 18 (78.3%) 2 (33.3%) 7.20 1.01-51.39
CD4 PV 0.023
Median (Min-Max) 1,488 (629-2,717) 689 (572-1,501) 21.69 1.53-308.25
CD4 7 years after PV 0.026
≤500 6 (26.1%) 5 (83.3%) 1.00
>500 17 (73.9%) 1 (16.7%) 14.17 1.37-147.07
CD4 7 years after PV 0.018
Median (Min-Max) 634 (188-1,295) 200 (9-737) 13.09 1.57-109.39
VL PV 0.137
≤400 9 (39.1%) 0 (0.0%) NE NE
>400 14 (60.9%) 6 (100.0%)
VL PV 0.244
Median (Min-Max) 700 (200-84,000) 1500 (760-24,000) 0.78 0.51-1.19
VL 7 years after PV 0.295
≤50 6 (27.1%) 0 (0.0%) NE NE
>50 17 (73.9%) 6 (100.0%)
VL 7 years after PV 0.095
Median (Min-Max) 1,277 (25-94,250) 14,004 (147-58,078) 0.68 0.43-1.07
Clinical Cat. PV 0.497
N or A 15 (65.2%) 3 (50.0%) 1.88 0.31-11.52
B 8 (34.8%) 3 (50.0%) 1.00
Clinical Cat. after 7 years 0.655
N or A 10 (43.5%) 2 (33.3%) 1.54 0.23-10.15
B or C 13 (56.5%) 4 (66.7%) 1.00
Imunol Cat. PV 0.509
1 7 (30.4%) 1 (16.7%) 2.19 0.21-22.34
2 or 3 16 (69.6%) 5 (83.3%) 1.00
Imunol Cat. after 7 years 0.634
1 6 (26.1%) 1 (16.7%) 1.77 0.17-18.32
2 or 3 17 (73.9%) 5 (83.3%) 1.00
Zoster 0.005
Absent 22 (95.7%) 2 (33.3%) 44.00 3.18-608.16
Present 1 (4.3%) 4 (66.7%) 1.00
Age at ART start 0.193
Median (Min-Max) 1.7 (0.1-5.6) 3.2 (1.7-4.3) 0.67 0.36-1.23
HAV AB after PV 0.008
Median (Min-Max) 2,070 (269-10,260) 296 (103-1,175) 9.04 1.77-46.21
HAV AB after PV 0.003
<1000 2 (8.7%) 5 (83.3%) 1.00
≥1000 21 (91.3%) 1 (16.7%) 52.50 3.93-700.53
NE, not estimable; PV, Primary vaccination for A hepatitis; VL, viral load; CD4, TCD4+ Lymphocytes; AB, Antibodies; Cat, category; 
Imunol, immunological; ART, antiretroviral therapy and HAV-Hepatitis A virus.
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that, over the seven-year period, the following data were 
observed (Fig. 3): a) the viral load increased in patients 1 
and 2; b) four patients (1, 3, 5 and 6) had clinical progres-
sion of the disease, aggravating their clinical category 
(CDC-1994); c) four patients (1, 2, 5 and 6) showed a wors-
ening in immunosuppression, aggravating their immunolog-
ical category (CDC-1994), and d) patients (2, 4 and 6), who 
had the highest concentrations of HAV antibodies after 
revaccination were the ones who had a higher CD4+ T cell 
count at the time of the primary immunization (Fig. 4). The 
only patient who did not respond to revaccination (patient 1 
in Fig. 4) was the one with the highest number of clinical 
complications, with important nutritional impairment, 
decreased z-BMI and immunological impairment in the peri-
od after vaccination. It is noteworthy that, at the time of 
the 1st revaccination dose, this adolescent had an undetect-
able viral load, responding with an antibody concentration 
of 19.7mIU/mL for HAV. As he started to show evidence of 
HIV viral replication, the antibody titers for HAV decreased 
again (Fig. 2), even though he received a 2nd booster dose 
and showed an increase in CD4+T cell count (from 65 cells/
mm3 to 285 cells/mm3 in the period between the 1st and 2nd 
revaccination doses).
The small number of sample subjects, particularly in the 
ENI Group, who typically abandon follow-up soon after 
their uninfected status is verified, and the great variability 
of data may have impaired the statistical analysis of our 
findings. Still, it was possible to demonstrate the impor-
tance of temporal monitoring of antibody levels after hep-
atitis A vaccine in HIV-infected patients.
Although all adolescents exposed and not infected with 
HIV remained seropositive for HAV, 21% of the HIV-infected 
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Figure 2 Dynamics of plasma levels of hepatitis A antibodies 
after revaccination in 6 patients from the HIV group without 
protective antibody levels seven years after primary 
immunization. Note: the sample from child #6 immediately 
before the 2nd booster dose was lost.
Table 3 Clinical manifestations shown by children who did not maintain protective levels of hepatitis A antibodies seven years 
after vaccination.
Patients Hospital 
admissions
Pneumonia Herpes 
Zoster
Upper respiratory 
tract infections
Chronic 
Otitis Media
Neurotoxoplasmosis Others
1 4 2 1 >10 episodes 2
2 2 1 1
3 2 1
4 1 0 1 Parotitis/
Gastritis
5 1 1 1 Diarrhea
6 1 Fractures
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Figure 3 Evolution of viral load at four different moments: 
30 days after primary vaccination (PV), seven years after PV, 
immediately before the 1st and 2nd booster dose (REVAC) in 
6 patients from the HIV group who did not respond to 
revaccination.
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adolescents lost the seropositivity for hepatitis A seven years 
after the primary immunization, particularly those with 
more clinical complications and more severe immunosup-
pression. However, it is encouraging to verify that revaccina-
tion determines antibody production response at levels >20 
mIU/mL in most assessed patients. It is noteworthy that no 
other studies in the literature have shown the association 
between post-vaccination antibody titers and their per-
sistence in the long term, or the possible association between 
clinical events and the maintenance of these antibodies.
To maintain protection against hepatitis B, there are 
national24 and international25 recommendations on the 
revaccination of immunosuppressed individuals who lost 
their antibodies. There is no such recommendation regard-
ing hepatitis A, but the data shown here suggest that, for 
children and adolescents infected with HIV, antibody titer 
monitoring is necessary, and revaccination is advisable to 
maintain protective levels of antibodies. It is known that 
HIV-infected patients should be vaccinated as early as pos-
sible, at a time when immunological impairment has not 
occurred yet. It can be concluded, based on the multivari-
ate analysis shown here, that the level of hepatitis A anti-
bodies in the first vaccination is the only factor inde-
pendently associated with the maintenance of these anti-
bodies after a period of seven years. This association was 
also observed by Sharapov et al.26 A less intense response at 
the primary vaccination suggests an immunological impair-
ment at this moment. Nevertheless, 83.3% of patients sero-
negative for hepatitis A responded to revaccination, 
although the duration of these antibodies is something to 
be studied in the future.
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